Leading the way to safer medication
 Crosscheck  Recommender

ATC Group: L04AA21 Efalizumab

Anatomical Therapeutic Chemical Classification System

Hierarchical Position

Level
Code
Title
1
L
Antineoplastic and immunomodulating agents
2
L04
Immunosuppressants
3
L04A
Immunosuppressants
4
L04AA
Selective immunosuppressants
5
L04AA21
Efalizumab

Active Ingredients

Chemical substance
Description
Efalizumab

Efalizumab is a recombinant humanized monoclonal antibody that binds specifically to the CD11a subunit of LFA-1 (lymphocyte function-associated antigen-1), a leukocyte cell surface protein. By this mechanism, efalizumab inhibits the binding of LFA-1 to ICAM-1, which interferes with T lymphocytes adhesion to other cell types. LFA-1 is present on activated T lymphocytes, and ICAM-1 is up-regulated on endothelial cells and keratinocytes in psoriasis plaques. By preventing LFA-1/ICAM binding, efalizumab may alleviate signs and symptoms of psoriasis by inhibiting several stages in the immunologic cascade.

Monographs

Monograph
Type
Country
RAPTIVA Powder and solvent for solution for injection
MPI, EU: SmPC